Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer

Charles C. Guo, Tadeusz Majewski, Li Zhang, Hui Yao, Jolanta Bondaruk, Yan Wang, Shizhen Zhang, Ziqiao Wang, June Goo Lee, Sang Kyou Lee, David Cogdell, Miao Zhang, Peng Wei, H. Barton Grossman, Ashish Kamat, Jonathan James Duplisea, James Edward Ferguson, He Huang, Vipulkumar Dadhania, Jianjun Gao & 5 others Colin Dinney, John N. Weinstein, Keith Baggerly, David McConkey, Bogdan Czerniak

Research output: Contribution to journalArticle

Abstract

Sarcomatoid urothelial bladder cancer (SARC) displays a high propensity for distant metastasis and is associated with short survival. We report a comprehensive genomic analysis of 28 cases of SARC and 84 cases of conventional urothelial carcinoma (UC), with the TCGA cohort of 408 muscle-invasive bladder cancers serving as the reference. SARCs show a distinct mutational landscape, with enrichment of TP53, RB1, and PIK3CA mutations. They are related to the basal molecular subtype of conventional UCs and could be divided into epithelial-basal and more clinically aggressive mesenchymal subsets on the basis of TP63 and its target gene expression levels. Other analyses reveal that SARCs are driven by downregulation of homotypic adherence genes and dysregulation of the EMT network, and nearly half exhibit a heavily infiltrated immune phenotype. Our observations have important implications for prognostication and the development of more effective therapies for this highly lethal variant of bladder cancer. Guo et al. report that sarcomatoid carcinoma of the bladder evolves by the progression of the basal subtype of conventional urothelial carcinoma with the enrichment of mutagenesis signature 1 and mutations of TP53, RB1, and PIK3CA. It is driven by the dysregulation of the EMT network and shows increased immune infiltrate with overexpression of PD-L1.

Original languageEnglish
Pages (from-to)1781-1793.e4
JournalCell Reports
Volume27
Issue number6
DOIs
Publication statusPublished - 2019 May 7

Fingerprint

Mutagenesis
Urinary Bladder Neoplasms
Gene expression
Muscle
Genes
Carcinoma
Mutation
Urinary Bladder
Down-Regulation
Neoplasm Metastasis
Phenotype
Gene Expression
Muscles
Therapeutics

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Guo, C. C., Majewski, T., Zhang, L., Yao, H., Bondaruk, J., Wang, Y., ... Czerniak, B. (2019). Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer. Cell Reports, 27(6), 1781-1793.e4. https://doi.org/10.1016/j.celrep.2019.04.048
Guo, Charles C. ; Majewski, Tadeusz ; Zhang, Li ; Yao, Hui ; Bondaruk, Jolanta ; Wang, Yan ; Zhang, Shizhen ; Wang, Ziqiao ; Lee, June Goo ; Lee, Sang Kyou ; Cogdell, David ; Zhang, Miao ; Wei, Peng ; Grossman, H. Barton ; Kamat, Ashish ; Duplisea, Jonathan James ; Ferguson, James Edward ; Huang, He ; Dadhania, Vipulkumar ; Gao, Jianjun ; Dinney, Colin ; Weinstein, John N. ; Baggerly, Keith ; McConkey, David ; Czerniak, Bogdan. / Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer. In: Cell Reports. 2019 ; Vol. 27, No. 6. pp. 1781-1793.e4.
@article{9aa86c28153649e89beaa6445e1d075a,
title = "Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer",
abstract = "Sarcomatoid urothelial bladder cancer (SARC) displays a high propensity for distant metastasis and is associated with short survival. We report a comprehensive genomic analysis of 28 cases of SARC and 84 cases of conventional urothelial carcinoma (UC), with the TCGA cohort of 408 muscle-invasive bladder cancers serving as the reference. SARCs show a distinct mutational landscape, with enrichment of TP53, RB1, and PIK3CA mutations. They are related to the basal molecular subtype of conventional UCs and could be divided into epithelial-basal and more clinically aggressive mesenchymal subsets on the basis of TP63 and its target gene expression levels. Other analyses reveal that SARCs are driven by downregulation of homotypic adherence genes and dysregulation of the EMT network, and nearly half exhibit a heavily infiltrated immune phenotype. Our observations have important implications for prognostication and the development of more effective therapies for this highly lethal variant of bladder cancer. Guo et al. report that sarcomatoid carcinoma of the bladder evolves by the progression of the basal subtype of conventional urothelial carcinoma with the enrichment of mutagenesis signature 1 and mutations of TP53, RB1, and PIK3CA. It is driven by the dysregulation of the EMT network and shows increased immune infiltrate with overexpression of PD-L1.",
author = "Guo, {Charles C.} and Tadeusz Majewski and Li Zhang and Hui Yao and Jolanta Bondaruk and Yan Wang and Shizhen Zhang and Ziqiao Wang and Lee, {June Goo} and Lee, {Sang Kyou} and David Cogdell and Miao Zhang and Peng Wei and Grossman, {H. Barton} and Ashish Kamat and Duplisea, {Jonathan James} and Ferguson, {James Edward} and He Huang and Vipulkumar Dadhania and Jianjun Gao and Colin Dinney and Weinstein, {John N.} and Keith Baggerly and David McConkey and Bogdan Czerniak",
year = "2019",
month = "5",
day = "7",
doi = "10.1016/j.celrep.2019.04.048",
language = "English",
volume = "27",
pages = "1781--1793.e4",
journal = "Cell Reports",
issn = "2211-1247",
publisher = "Cell Press",
number = "6",

}

Guo, CC, Majewski, T, Zhang, L, Yao, H, Bondaruk, J, Wang, Y, Zhang, S, Wang, Z, Lee, JG, Lee, SK, Cogdell, D, Zhang, M, Wei, P, Grossman, HB, Kamat, A, Duplisea, JJ, Ferguson, JE, Huang, H, Dadhania, V, Gao, J, Dinney, C, Weinstein, JN, Baggerly, K, McConkey, D & Czerniak, B 2019, 'Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer', Cell Reports, vol. 27, no. 6, pp. 1781-1793.e4. https://doi.org/10.1016/j.celrep.2019.04.048

Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer. / Guo, Charles C.; Majewski, Tadeusz; Zhang, Li; Yao, Hui; Bondaruk, Jolanta; Wang, Yan; Zhang, Shizhen; Wang, Ziqiao; Lee, June Goo; Lee, Sang Kyou; Cogdell, David; Zhang, Miao; Wei, Peng; Grossman, H. Barton; Kamat, Ashish; Duplisea, Jonathan James; Ferguson, James Edward; Huang, He; Dadhania, Vipulkumar; Gao, Jianjun; Dinney, Colin; Weinstein, John N.; Baggerly, Keith; McConkey, David; Czerniak, Bogdan.

In: Cell Reports, Vol. 27, No. 6, 07.05.2019, p. 1781-1793.e4.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer

AU - Guo, Charles C.

AU - Majewski, Tadeusz

AU - Zhang, Li

AU - Yao, Hui

AU - Bondaruk, Jolanta

AU - Wang, Yan

AU - Zhang, Shizhen

AU - Wang, Ziqiao

AU - Lee, June Goo

AU - Lee, Sang Kyou

AU - Cogdell, David

AU - Zhang, Miao

AU - Wei, Peng

AU - Grossman, H. Barton

AU - Kamat, Ashish

AU - Duplisea, Jonathan James

AU - Ferguson, James Edward

AU - Huang, He

AU - Dadhania, Vipulkumar

AU - Gao, Jianjun

AU - Dinney, Colin

AU - Weinstein, John N.

AU - Baggerly, Keith

AU - McConkey, David

AU - Czerniak, Bogdan

PY - 2019/5/7

Y1 - 2019/5/7

N2 - Sarcomatoid urothelial bladder cancer (SARC) displays a high propensity for distant metastasis and is associated with short survival. We report a comprehensive genomic analysis of 28 cases of SARC and 84 cases of conventional urothelial carcinoma (UC), with the TCGA cohort of 408 muscle-invasive bladder cancers serving as the reference. SARCs show a distinct mutational landscape, with enrichment of TP53, RB1, and PIK3CA mutations. They are related to the basal molecular subtype of conventional UCs and could be divided into epithelial-basal and more clinically aggressive mesenchymal subsets on the basis of TP63 and its target gene expression levels. Other analyses reveal that SARCs are driven by downregulation of homotypic adherence genes and dysregulation of the EMT network, and nearly half exhibit a heavily infiltrated immune phenotype. Our observations have important implications for prognostication and the development of more effective therapies for this highly lethal variant of bladder cancer. Guo et al. report that sarcomatoid carcinoma of the bladder evolves by the progression of the basal subtype of conventional urothelial carcinoma with the enrichment of mutagenesis signature 1 and mutations of TP53, RB1, and PIK3CA. It is driven by the dysregulation of the EMT network and shows increased immune infiltrate with overexpression of PD-L1.

AB - Sarcomatoid urothelial bladder cancer (SARC) displays a high propensity for distant metastasis and is associated with short survival. We report a comprehensive genomic analysis of 28 cases of SARC and 84 cases of conventional urothelial carcinoma (UC), with the TCGA cohort of 408 muscle-invasive bladder cancers serving as the reference. SARCs show a distinct mutational landscape, with enrichment of TP53, RB1, and PIK3CA mutations. They are related to the basal molecular subtype of conventional UCs and could be divided into epithelial-basal and more clinically aggressive mesenchymal subsets on the basis of TP63 and its target gene expression levels. Other analyses reveal that SARCs are driven by downregulation of homotypic adherence genes and dysregulation of the EMT network, and nearly half exhibit a heavily infiltrated immune phenotype. Our observations have important implications for prognostication and the development of more effective therapies for this highly lethal variant of bladder cancer. Guo et al. report that sarcomatoid carcinoma of the bladder evolves by the progression of the basal subtype of conventional urothelial carcinoma with the enrichment of mutagenesis signature 1 and mutations of TP53, RB1, and PIK3CA. It is driven by the dysregulation of the EMT network and shows increased immune infiltrate with overexpression of PD-L1.

UR - http://www.scopus.com/inward/record.url?scp=85064861998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064861998&partnerID=8YFLogxK

U2 - 10.1016/j.celrep.2019.04.048

DO - 10.1016/j.celrep.2019.04.048

M3 - Article

VL - 27

SP - 1781-1793.e4

JO - Cell Reports

JF - Cell Reports

SN - 2211-1247

IS - 6

ER -